CRON
Cronos Group Inc
NASDAQ: CRON · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$3.14
-0.63% today
Updated 2026-09-11
Market cap
$1.16B
P/E ratio
16.53
P/S ratio
6.46x
EPS (TTM)
$0.19
Dividend yield
—
52W range
$2 – $4
Volume
1.2M
WallStSmart proprietary scores
61
out of 100
Grade: C+
Hold
Investment rating
9.3
Growth
A+9.0
Quality
A+5.5
Profitability
C+6.0
Valuation
B5/9
Piotroski F-Score
Moderate
14.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$2.53
-19.46%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 14.15 — safe zone
+ Profit margin 39.10% — above average
+ Free cash flow $17.05M — positive
+ Revenue growth 58.40% QoQ
+ Debt/equity 0.00x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $86.75M | $87.24M | $117.61M | $149.15M | $179.09M |
| Net income | $-168.73M | $-73.96M | $41.08M | $-9.61M | $32.09M |
| EPS | — | — | — | — | $0.19 |
| Free cash flow | $-93.98M | $-46.26M | $5.69M | $151611.00 | $17.05M |
| Profit margin | -194.51% | -84.78% | 34.93% | -6.44% | 39.10% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-12 | WAGNER, ADAM | Sale | 10,367 | — |
| 2026-05-12 | WAGNER, ADAM | Buy | 10,367 | — |
| 2026-05-12 | KENOST, JARED MATTHEW | Buy | 30,000 | — |
Peer comparison
Smart narrative
Cronos Group Inc trades at $3.14. representing a P/E of 16.53x trailing earnings. Our Smart Value Score of 61/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 14.15, it sits in the safe zone. TTM revenue stands at $179.09M. with profit margins at 39.10%.
Frequently asked questions
What is Cronos Group Inc's stock price?
Cronos Group Inc (CRON) trades at $3.14, on a P/E of 16.5x and a P/S of 6.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Cronos Group Inc overvalued?
Cronos Group Inc carries a Smart Value Score of 61/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Cronos Group Inc (CRON)?
The 12-month analyst consensus target is $2.53, about 19.5% below the current $3.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Cronos Group Inc's revenue?
Cronos Group Inc's trailing twelve-month revenue is $179.09M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Cronos Group Inc's Altman Z-Score is 14.15, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.46x
ROE-0.19%
Beta1.28
50D MA$3.03
200D MA$2.75
Shares out0.37B
Float0.19B
Short ratio—
Avg volume1.2M
Performance
1 week+0.00%
1 month-4.58%
3 months+8.40%
YTD+3.04%
1 year—
3 years—
5 years—